Golden Biotechnology Corporation (TPEX:4132)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
3.470
0.00 (0.00%)
Apr 9, 2026, 2:59 PM CST
-72.46%
Market Cap 562.93M
Revenue (ttm) 44.58M
Net Income (ttm) -314.93M
Shares Out 162.23M
EPS (ttm) -1.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 7,061,471
Average Volume 5,360,770
Open 4.850
Previous Close 3.470
Day's Range 3.470 - 5.090
52-Week Range 3.470 - 36.300
Beta 1.08
RSI 21.18
Earnings Date Apr 27, 2026

About Golden Biotechnology

Golden Biotechnology Corporation operates as a drug discovery and healthy food supplement manufacturing company in Taiwan, the United States, Japan, China, Korea, and Singapore. Its products include Liverty that is used for liver health support and fatigue; Rasle, an auto-immune adjuvant therapy; ZSAINO, a nourishment product for recovery from illness and for health improvement; and UMOOZE, a herbal formula for optimal health in males. The company also provides Antroquinonol, an anticancer molecule for the treatment of pancreatic cancer, acute ... [Read more]

Sector Healthcare
Founded 2002
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 4132
Full Company Profile

Financial Performance

In 2024, Golden Biotechnology's revenue was 40.92 million, a decrease of -35.49% compared to the previous year's 63.43 million. Losses were -360.70 million, -0.26% less than in 2023.

Financial Statements

News

There is no news available yet.